01 A specialized translation program in quiescent cancer cells. Shobha Vasudevan, MGH-Harvard Medical School, Boston, MA, United States.

02 BCL-W significantly contributes to B cell lymphoma survival and development. Clare Adams, Thomas Jefferson University, Philadelphia, PA, United States.

03 Probing mitochondria to guide personalized therapy for acute myeloid leukemia. Shruti Bhatt, Dana-Farber Cancer Institute, Boston, MA, United States.

04 p53-related protein kinase is a novel prognostic marker and therapeutic target in multiple myeloma. Francesca Cottini, The Ohio State University, Columbus, OH, United States.


06 SY-1425 (tamibarotene), a potent and selective RARα agonist, induces changes in the transcriptional regulatory circuit of AML cells leading to differentiation. Christopher Fiore, Syros Pharmaceuticals, Cambridge, MA, United States.

07 Polycomb repressive complex 2 inactivation induces primary chemotherapy resistance in T-ALL by upregulating the TRAP1 mitochondrial chaperone. Alejandro Gutierrez, Boston Children's Hospital, Boston, MA, United States.

08 Soluble agonists in the in vivo macroenvironment generate phenotypic de novo resistance to BTK/Bcl-2 targeted therapies in diverse B cell malignancies. Kallesh Jayappa, University of Virginia, Charlottesville, VA, United States.

09 Therapeutic synergy between Tigecycline and Venetoclax in a pre-clinical model of MYC/BCL2 double-hit lymphoma. Micol Ravà, Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia (IIT), Milan, Italy.

10 Degradation of leukemia oncogenes: A novel approach to therapy of leukemia. Sara Buhrlage, Dana-Farber Cancer Institute, Boston, MA, United States.

11 Progression from newly diagnosed multiple myeloma to relapsed refractory multiple myeloma is associated with significant alterations in the CD4+ Treg population phenotype. Rachel Cooke, Royal Melbourne Hospital, Melbourne, Vic, Australia.

12 KMD6A/UTX loss enhances the malignant phenotype of multiple myeloma and sensitizes cells to EZH2 inhibition. Daphne Dupere-Richer, The University of Florida Health Cancer Center, Gainesville, FL, United States.

13 PRMT1 as a therapeutic target in diffuse large B-cell lymphoma. Aarthi Goverdhan, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
14  BRD9 defines a novel mammalian SWI/SNF (BAF) complex configuration which supports proliferation in AML. Brittany Michel, Dana-Farber Cancer Institute, Boston, MA, United States.

15  Characterization of lineage vs. context-dependent essential genes in multiple myeloma using CRISPR/Cas9 genome editing. Constantine Mitsiades, Dana-Farber Cancer Institute, Boston, MA, United States.

16  Genomic landscape of adult mixed phenotype acute leukemia (MPAL). Koichi Takahashi, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

17  In situ immune expression signatures before and after ipilimumab therapy for relapsed acute myeloid leukemia after allogeneic stem cell transplantation. Pavan Bachireddy, Dana-Farber Cancer Institute, Boston, MA, United States.

18  Evaluating the contribution of anti-myeloma immunity for the efficacy of oncolytic reovirus therapy. Louise Müller, University of Leeds, Leeds, United Kingdom.

19  Hypomethylating agent, SGI-110, alters the immunosuppressive milieu in acute myeloid leukemia (AML) and enhances the immunogenicity of a dendritic cell/AML fusion vaccine. Myrna Nahas, Beth Israel Deaconess Medical Center, Boston, MA, United States.


23  An AML patient derived monoclonal antibody recognizes a unique CD43 epitope expressed on all myeloid leukemias and shows strong anti-tumor reactivity in vivo. Mette Hazenberg, Academic Medical Center, Amsterdam, Netherlands.


25  CG’806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3. Weiguo Zhang, UT MD Anderson Cancer Center, Houston, TX, United States.

26  RUNX1 as a transcriptional target of activated Shp2 (PTPN11) in juvenile myelomonocytic leukemia. Alan Cantor, Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA, United States.

28 The novel role of FOXM1 in AML. Andrei Gartel, University of Illinois at Chicago, Chicago, IL, United States.

29 Characterization and treatment of a novel adoptive transfer model of Sf3b1mut/Atmdel Chronic Lymphocytic Leukemia. Elisa ten Hacken, Dana Farber Cancer Institute, Boston, MA, United States.

30 SOX9 enhancer regulator may play an oncogenic role in B-Cell lymphomas. Angela Fachel, Weill Cornell Medicine, New York City, NY, United States.

31 T-cell lymphomas have targetable dependences on BCL-2, BCL-xL, and MCL-1. Raphael Koch, Dana-Farber Cancer Institute, Boston, MA, United States.

32 FBXO11 is recurrently mutated in Burkitt lymphoma and its inactivation accelerates lymphomagenesis in Eμ-myc mice. Chiara Pighi, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.

33 Clinicopathological, immunophenotypic, diagnostic, treatment characteristics of non-Hodgkin's lymphoma: Diffuse large B cell: Primary ovarian and with ovarian extensive involvement. Tara Rajendran, Kasturba Medical College Manipal University, Mangalore, Karnataka, India.

34 Bleomycin pulmonary toxicity in Hodgkin's lymphoma treated with ABVD regimen not followed by radiation. Tara Rajendran, Kasturba Medical College Manipal University, Mangalore, Karnataka, India.

35 Differential expression of intracellular signaling molecules p-ERK, MYC, and p-STAT3 in enhancer of Zeste Homolog 2 (EZH2) protein-positive T-cell neoplasms. Xuejun Tian, Albert Einstein College of Medicine, Bronx, NY, United States.

36 Preclinical models of multiple myeloma. Erin Trachet, MI Bioresearch, Ann Arbor, MI, United States.

37 An unusual case of myelofibrosis with a JAK2 H538QK539L mutation associated with nephrotic syndrome. Moon Ley Tung, National University Cancer Institute, Singapore, Singapore.

38 Modeling clonal hematopoietic disorders in zebrafish using combinatorial mutagenesis and color barcoding. Serine Avagyan, Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA, United States.

39 XPO1 inhibitor, KPT-8602, is well tolerated and highly active against AML blasts and LICs. Julia Etchin, Dana-Farber Cancer Institute, Boston, MA, United States.
40 MicroRNA-130a regulates hematopoietic stem cell self-renewal and erythroid differentiation. Gabriela Krivdova, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

41 TOX is a novel oncogenic driver in T-cell acute lymphoblastic leukemia and regulates non-homologous end joining DNA repair. David Langenau, Massachusetts General Hospital, Boston, MA, United States.

42 MYC through HIF-2α regulates the altruistic stemness program in human leukemia stem cells. Bidisha Pal, Forsyth Institute, Cambridge, MA, United States.


44 CG’806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes. Stephen Kurtz, Oregon Health & Science University, Portland, OR, United States.

45 BTM-3528 potently induces G1/G0 cell cycle arrest and is efficacious in preclinical models of diffuse large B cell lymphoma. Jedd Levine, Bantam Pharmaceutical, Boston, MA, United States.


47 A clinically curative combination therapy acts by low cross-resistance between drugs, not by synergistic interactions between drugs. Adam Palmer, Harvard Medical School, Boston, MA, United States.

48 Acid ceramidase inhibition: A targeted therapy for acute myeloid leukemia. Jennifer Pearson, University of Virginia, Charlottesville, VA, United States.

49 Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Marta Sanchez-Martin, Columbia University, New York, New York, United States.

50 Small molecule Ring1B-Bmi1 inhibitor attenuates PRC1 E3 ligase activity and target leukemia stem cells self-renewal. Shirish Shukla, University of Michigan, Ann Arbor, MI, United States.

51 The eukaryotic translation initiation factor 4H regulates proliferation, migration and invasion in cancer cells. Manohar Singh, Central Drug Research Institute, Lucknow, Uttar Pradesh, India.

52 Antitumor activity of entrectinib, a highly potent pan-TRK, ROS1, and ALK inhibitor, in NTRK-fusion positive acute myeloid leukemia. Kristen Smith, Ignyta, San Diego, CA, United States.

53 Expression of EBV in the non-neoplastic cell population in trephine biopsies of patients with multiple myeloma is associated with a significant survival advantage. Sheerien Rajput, The Aga Khan University, Karachi, Pakistan.
54 MUC1-C regulates PD-L1 expression in acute myeloid leukemia, via down-regulation of miRNAs. Dina Stroopinsky, Beth Israel Deaconess Medical Center/ Harvard Medical School, Boston, MA, United States.

55 Multiple myeloma malignant reprogramming is promoted by ADAR1-dependent recoding of stem cell agonist GLI1. Elisa Lazzari, UCSD Moores Cancer Center, La Jolla, CA, United States.